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erate hemophilia (p= 0.01), HIV (p< 0.01), HCV (p= 0.02), and factor usage (p= 0.02) 
were significantly associated with ABF. Fewer variables had a significant associa-
tion with ABF for children compared to adults, including prophylaxis (p< 0.01) and 
factor usage (p= 0.01). ConClusions: Variables associated with ABF include socio-
demographics, clinical characteristics and factor usage. The preliminary results 
reinforce the importance of optimizing treatment for individual differences. Future 
studies should investigate how variations in bleeding outcomes and treatment are 
associated with healthcare costs.
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PRM1
CART ANAlySIS AS A TOOl TO DETERMINE OPTIMAl TREATMENT 
INTENSIfICATION TIME IN DIAbETES
Watson L1, Farquhar R2, Das R3, Flynn A2
1Explore-Epi Ltd, Mattishall, UK, 2Exploristics Ltd, Belfast, UK, 3Merck Sharp & Dohme Limited, 
Hoddesdon, UK
objeCtives: A key objective of treating type 2 diabetes mellitus (TD2M) is main-
taining glycaemic control, (glycated haemoglobin-HbA1c) with targets set between 
6.5%-7.5%. Doctors frequently fail to intensify treatment in uncontrolled patients 
and a study was designed to assess the long term clinical effects of this inertia. The 
study involved Classification and Regression Tree (CART) analyses to evaluate the 
timepoint that intensification should occur to gain glycaemic control. Methods: 
Incident T2DM patients were identified in the UK CPRD database between 1 January 
2000-31 August 2014 and followed for 5 years. Patients initiated on metformin 
monotherapy and did not achieved HbA1c< 7% after 90 days. CART was applied, 
with Hba1c level as the dependent variable and three explanatory effects: time to 
intensification class (TTIc), Year and Year by TTIc interaction. For each iteration TTIc 
was assigned per subject (i.e. those patients with TTI before or after TTI cut-point). 
The goodness of fit, the Akaike Information Criteria (AIC), was obtained for the 
model and the optimal cut point was the one resulting in the lowest AIC value. This 
created two classes of subjects, rapid and delayed TTI, whose HbA1c values were 
compared Results: The model identified that the optimal intensification time 
was ≤ 244 days post the first HbA1c≥ 7% (rapid TTI). 50.7% of patients with rapid TTI 
achieved HbA1c target< 7%, compared to only 14.0% in delayed TTI, despite rapid 
patients starting with higher average HbA1c levels (8.65%) than delayed patients 
(7.85%). The effects of rapid intensification caused immediate and maintained 
reduction in glucose levels, not observed in the delayed group. ConClusions: 
CART analysis identified the optimal timing for treatment intensification post loss 
of glycaemic control as ≤ 244 days. This analytical method could be used in future 
database studies to aid in group definition by treatment exposure and provide valu-
able clinical information for physicians.
PRM2
HOw TO CONDUCT ECONOMIC EVAlUATIONS Of NEw TREATMENTS fOR 
ADVANCED CANCER wHEN OVERAll SURVIVAl DATA ARE NOT AVAIlAblE? 
RESUlTS fROM A SySTEMATIC lITERATURE REVIEw
Beauchemin C1, Lapierre M1, Letarte N1, Yelle L2, Lachaine J1
1University of Montreal, Montreal, QC, Canada, 2Centre Hospitalier de l’Université de Montréal – 
Hôpital Notre-Dame, Montreal, QC, Canada
objeCtives: Use of surrogate endpoints like progression-free survival (PFS) and 
time to progression (TTP) instead of overall survival (OS) in clinical trials for 
advanced cancer remains challenging from a health economic standpoint. This 
study assessed the use of surrogate endpoints in economic evaluations of anticancer 
drugs and methodological approaches adopted when reliable OS data are unavail-
able. Methods: A systematic literature review was conducted to identify economic 
evaluations of treatments for advanced cancer published between January 2003 
and October 2013. Cost-effectiveness and cost-utility analyses expressed in terms 
of cost per life-year gained and cost per quality-adjusted life-year using a surrogate 
endpoint as an outcome measure were eligible. Characteristics of selected stud-
ies were extracted and comprised: population, treatment of interest, comparator, 
line-of-treatment, study perspective, and time horizon. Use of surrogate endpoints 
and methods adopted when OS data were lacking were analyzed. Two reviewers 
independently selected studies and extracted data. Results: In total, 7,219 stud-
ies were identified and 100 fulfilled the eligibility criteria. Most included studies 
assessed the cost-effectiveness of a biological therapy (65%) in the first-line setting 
(56%) and in the context of advanced non-small cell lung cancer (24%) or advanced 
breast cancer (22%). Surrogate endpoints mostly used were PFS and TTP, account-
ing for 92% of included studies. OS data were unavailable for analysis in nearly 
25% of economic evaluations. In the absence of OS data, studies most commonly 
assumed an equal risk of death for all treatment groups. Other methods included 
use of indirect comparison based on numerous assumptions, use of a surrogate 
endpoint as a proxy for OS, consultation with clinical experts, and use of OS data 
associated with different patient populations or treatment-line. ConClusions: 
Although several approaches are used, there is no consensus method to estimate 
the cost-effectiveness of new anticancer drugs in the absence of reliable OS data.
PRM3
SElECTION Of STATISTICAl APPROACH IN UNDERSTANDINg THE ROlE 
Of CONTRAST MEDIA IN INPATIENT INTERVENTIONAl CARDIOVASCUlAR 
PROCEDURES
David G1, Johnson M2, Lim L3, Mallow PJ4
(MM). Methods: Telephone interviews lasting approximately 1 hour were conducted 
with two HTA experts from each country, based on an interview guide. Interviews were 
recorded and common themes identified from assessment of the narrative. Results: 
The French advisors considered that the cost savings realized through informal care 
compared with formal caregiving are neglected, and that data on informal caregiver 
burden should be incorporated into cost-effectiveness models where available. The 
German advisors suggested that caregiver burden may be recognized in HTA if it can 
be related to patient benefit. Discussions in this area are increasing but changes to 
the acceptability of caregiver burden data was mostly likely to occur elsewhere in the 
healthcare system (i.e., outside of the benefit assessment process). Advisors in the US 
reported that payers’ views of caregiver burden are changing and that this information 
should be considered as more patients involve their caregivers in decision-making, or 
caregivers make the decisions (for some groups of patients). ConClusions: Informal 
caregiver burden data are not currently considered important in HTA in Europe or 
the US, although there are suggestions that this may change. Even where such data 
have been included in HTA submissions, they have not generally been a driver of 
HTA decision-making.
PSy133
ASSESSMENT Of REAl-wORlD TREATMENT PATTERNS AND OUTCOMES IN 
RElAPSED OR REfRACTORy MUlTIPlE MyElOMA: EVIDENCE fROM A bRIEf 
MUlTI-COUNTRy SURVEy Of EUROPEAN PHySICIANS
Davis KL1, Lin HM2, Hui A2, Zhang S3, Kaye JA4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Millennium Pharmaceuticals, Inc., a 
wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA, USA, 
3Takeda Pharmaceuticals International, Inc., Deerfield, IL, USA, 4RTI Health Solutions, Waltham, 
MA, USA
objeCtives: Data from real-world European settings describing treatment patterns 
and outcomes in relapsed/refractory multiple myeloma (RRMM) are limited. This 
study helps address this knowledge gap using a brief physician survey. Methods: 
Sixty-one physicians treating RRMM were surveyed (November 2014) in France 
(n= 21), Germany (n= 20), and the United Kingdom (UK) (n= 20). The survey collected 
physicians’ opinions on typical treatment patterns and outcomes of RRMM patients 
in the relapse/refractory setting (following disease progression during/after first-
line therapy). Analyses were descriptive. Results: Sixty percent of physicians in 
France and the UK were haematologists, versus 10% in Germany (where 80% were 
onco-haematologists). The proportion of patients with high-risk disease based on 
ISS stage and cytogenetics was 18%-24% across countries. Bortezomib/thalidomide/
dexamethasone was the most common induction regimen (42%) for stem cell trans-
plant (SCT)-eligible patients in France, but was unused in Germany and less com-
monly prescribed in the UK (17%); bortezomib/cyclophosphamide/dexamethasone 
was the reported induction therapy for 28% of SCT-eligible patients in all coun-
tries. Regardless of SCT status, lenalidomide/dexamethasone was the predominant 
second-line treatment (37%-48%) reported in France and Germany; in the UK, 
second-/later-line regimens were more varied, with both lenalidomide- and bort-
ezomib-based regimens being reported as common. Second-/later-line therapy dura-
tion was generally short, particularly in the UK where 75% of physicians reported 
a < 6-month duration. Disease progression was the top reason for second/later-
line discontinuation; other common reasons included toxicity and completion of 
planned therapy course. For high-risk patients, > 75% of physicians reported median 
survival of < 1 year from first relapse. ConClusions: The proportion of RRMM 
patients with high-risk disease in real-world settings (18%-24%) may exceed that 
reported in clinical trials (10%-15%). Second-/later-line therapy duration is typically 
short (< 6 months). Survival prospects for RRMM patients remain limited, particu-
larly for high-risk patients. Patient-level studies are needed to better characterize 
the unmet needs in RRMM signaled by our findings.
PSy134
CHARACTERISTICS ASSOCIATED wITH ANNUAl blEEDINg fREqUENCy 
AMONg HEMOPHIlIA PATIENTS IN THE UNITED STATES
Chen CX1, Ullman MM2, Hord JD3, Kulkarni R4, Konkle BA5, Baker JR6, Riske B7, Koerper M8, 
Lou M1, Wu J1, Nichol MB1
1University of Southern California, Los Angeles, CA, USA, 2University of Texas at Houston, Gulf 
States Hemophilia and Thrombophilia Center, Houston, TX, USA, 3Akron Children’s Hospital, 
Akron, OH, USA, 4Michigan State University, East Lansing, MI, USA, 5Bloodworks NW, Seattle, 
WA, USA, 6University of California, Los Angeles, Los Angeles, CA, USA, 7University of Colorado 
Hemophilia and Thrombosis Center, Aurora, CO, USA, 8University of California, San Francisco, San 
Francisco, CA, USA
objeCtives: Bleeding episodes pose significant economic and quality-of-life (QoL) 
burdens on persons with hemophilia. This study aims to identify socio-demo-
graphic and clinical characteristics associated with annual bleeding frequency 
(ABF). Methods: Between 2005-2007 and 2009-2012, the Hemophilia Utilization 
Group Studies Va and Vb, respectively, recruited hemophilia A or B patients from 
ten geographically diverse Hemophilia Treatment Centers in the United States. 
Adult patients or parents of children completed a baseline survey that collected 
information regarding socio-demographics, clinical characteristics, and treatment 
patterns. During the two-year observation period, bleeding episodes were collected 
through regular patient follow-ups. ABF was calculated as the annualized sum of 
patient-reported bleeding episodes. Two-year drug dispensing information was also 
recorded and annualized. Multivariable linear regressions were used to assess the 
association of patient variables with ABF. Results: Of 477 recruited patients, 317 
with complete baseline and utilization data and at least three months of patient 
follow-up were included. Among included patients, 49.8% were children, 39.7% used 
prophylaxis, and 63.1% had severe hemophilia. Variables significantly associated 
with ABF included 37 or older vs. 2-9 years of age (p= 0.03), married or with a partner 
(p= 0.03), hemophilia B (p= 0.09), mild/moderate hemophilia (p= 0.01), prophylaxis 
(p< 0.01), human immunodeficiency virus (HIV) (p< 0.01), hepatitis C virus (HCV) 
(p< 0.01), and annual factor usage per kilogram of body weight (p< 0.01). Among 
adults, age in years (p= 0.07), no insurance vs. public insurance (p= 0.04), mild/mod-
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PRM6
THE ACCEPTANCE Of MORbIDITy ENDPOINTS IN THE AMNOg PROCESS 
IN gERMANy: ARE THERE gREATER HURDlES fOR SUbSTANCES wITHIN 
ONCOlOgy?
Bakker K, Volmer T
SmartStep Consulting GmbH, Hamburg, Germany
objeCtives: The objective of this study is to assess the acceptance of morbidity 
endpoints by the Institute for Quality and Efficiency in Healthcare (IQWiG) within 
the early benefit assessment in Germany. The analysis focuses on morbidity end-
points (ME) for oncology substances compared to non-oncology substances: (1) 
how many ME have been accepted? (2) In how many cases has IQWiG determined 
an additional benefit based on ME? Methods: All benefit assessments published 
by the Federal Joint Committee (G-BA) between 01/01/2011 and 12/05/2015 have 
been considered (n= 126). Of those, 80 were excluded from the analysis due to 
one of the following reasons: orphan drug designation, no dossier submitted or 
incomplete evaluation by the IQWiG (due to missing data). Data analyzed: num-
ber of accepted ME as proportion of all submitted endpoints; additional benefit 
based on accepted ME; percent of assessments in which at least one ME was 
accepted. Results: In total, 19 oncology and 27 non-oncology assessments 
have been included into the analysis. For the 19 oncology assessments, a total 
of 76 ME had been submitted. IQWiG accepted hereof 20 ME (≈26%). Accepted ME 
include: pain, skeletal-related complications and symptoms. The IQWiG deter-
mined an additional benefit for six assessments based on ME (6/19≈32%). For the 
27 non-oncology assessments, 127 ME had been submitted. IQWiG accepted 79 
(≈62%) including: strokes, cardiovascular events and relapse-related events. For 
non-oncology substances, IQWiG determined an additional benefit for thirteen 
assessments based on ME (13/27≈48%). At least one endpoint was accepted in 
83% of oncology assessments and in 100% of benefit assessments in all other 
indications. ConClusions: Though the rate of accepting ME in oncology indica-
tions is numerically lower (32% vs. 48%), the difference does not reach statistical 
significance (p= 0.36 Fisher’s exact test).
PRM7
COMPARISON Of TREATMENT-RElATED ADVERSE EVENTS RECORDED IN 
ADMINISTRATIVE ClAIMS DATA wITH THOSE RECORDED IN ElECTRONIC 
MEDICAl RECORDS fOR MUlTIPlE MyElOMA PATIENTS
Irwin DE1, Varker H2, Farr AM2
1Truven Health Analytics, Chapel Hill, NC, USA, 2Truven Health Analytics, Bethesda, MD, USA
objeCtives: Multiple myeloma patients often experience adverse events 
(AEs) related to treatment with novel therapies or traditional chemotherapy. 
Observational studies frequently use administrative claims data or electronic medi-
cal records (EMR) to assess potential AEs. The purpose of this analysis is to compare 
the occurrence of AEs identified in claims data with those recorded in an oncol-
ogy EMR. Methods: Multiple myeloma cases (n= 278) in the MarketScan Oncology 
EMR-Claims Linked Dataset who received novel or traditional chemotherapy were 
included. The index date was the first date of medication administration/order and 
patients were followed for AEs, including neutropenia, thrombocytopenia, venous 
thromboembolism (VTE) and diarrhea, until a > = 90 gap in all medications for the 
first regimen. Results: Neutropenia and thrombocytopenia were recorded less 
often in claims (neutropenia 9%; thrombocytopenia 7%) compared to EMR data 
(neutropenia 12%; thrombocytopenia 11%). Neutropenia and thrombocytopenia are 
monitored by oncologists with lab values and this may lead to more frequent record-
ing of less severe AEs in the EMR not reflected in claims data. VTE and diarrhea were 
recorded more often in the claims (VTE 9%; diarrhea 7%) compared to the EMR (VTE 
4%; diarrhea 4%). A VTE diagnosis may likely result in hospitalization and patients 
with diarrhea may seek care outside of their oncology practice; hence, claims data 
may capture additional diagnoses assigned by clinicians other than oncologists. 
Overall, the highest proportions of AEs were found with the linked data contain-
ing both the claims and EMR (neutropenia 19%, thrombocytopenia 16%, VTE 10%, 
diarrhea 11%). ConClusions: AEs typically monitored by lab values ordered by 
oncologists were recorded more often in EMR data and AEs potentially diagnosed by 
clinicians in settings outside the oncology practice were recorded more often in the 
claims data. The linked claims-EMR data provided the most complete assessment 
of potential treatment-related AEs.
PRM8
NON-COMPARATIVE TRIAlS TO SUPPlEMENT NETwORk META-ANAlySES 
USINg ARM-SPECIfIC META-REgRESSION: AN APPlICATION TO COMbINATION 
THERAPIES IN HIV
Kanters S1, Druyts E2, Jansen JP3, Mills EJ4, Thorlund K1
1Redwood Outcomes, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, BC, 
Canada, 3Redwood Outcomes, San Francisco, CA, USA, 4Stanford University, Stanford, CA, USA
objeCtives: There is a growing call for the use of endonodal trials within network 
meta-analyses (NMA), such as for informative priors or improved connectivity. 
Endonodal trials can also be used to further inform arm-specific meta-regression 
coefficients, which may be used to simplify node definitions in combination therapy. 
We applied this concept to a network of first line antiretroviral therapy (ART) to 
determine if efavirenz (EFV) still belongs in the preferred regimen. Methods: We 
conducted a systematic search of electronic databases up to March 1, 2015. Nodes 
were defined as specific antivirals rather than ART regimens, which simplified 
interpretation of modeling and results. Backbone regimens were categorized and 
arm-specific meta-regression used to adjust estimates accordingly. The alterna-
tive approach was to simply reduce the evidence base to trials that did not differ 
with respect to backbones. The most notable trial to differ in backbones was the 
SINGLE trial comparing EFV to dolutegravir (DTG), central to the research ques-
tion. Results: A total of 71 trials with 35,270 randomized patients informed the 
evidence base. DTG was found to be superior with respect to viral suppression at all 
time points (odds ratio [OR]: 1.87 at 48 weeks; 95% credible interval [CrI]: 1.34 – 2.64). 
Both DTG (OR: 0.26; 95% CrI: 0.15, 0.44) and low-dose EFV (OR: 0.39; 95% CrI: 0.17, 0.83) 
1The Wharton School, University of Pennsylvania, Philadelphia, PA, USA, 2GE Healthcare, Chalfont 
St Giles, UK, 3GE Healthcare, Marlborough, MA, USA, 4CTI Clinical Trial and Consulting Services, 
Cincinnati, OH, USA
objeCtives: The decision to utilize a particular product may depend on for-
mal hospital guidelines, physician practice patterns, negotiated reimbursement 
schedules with insurance companies, and other local (geographic and/or hospi-
tal) characteristics. These elements are mostly unobservable for the purpose of 
statistical inference. A hospital fixed-effects model specification, in essence, con-
trols for unobservable within-hospital time-invariant characteristics. Focusing on 
the relationship between iso-osmolar contrast media (CM) and low-osmolar CM 
agents (LOCM) and renal failure events in patients undergoing inpatient inter-
ventional procedures, this study highlights the importance of controlling for such 
factors by comparing statistical specifications with and without hospital fixed-
effects. Methods: The Premier database was used to identify patients between 
January 2008 and September 2013. Eligible patients had a primary procedure of 
angioplasty defined by International Classification of Diseases, 9th Revision (ICD-
9) and/or Current Procedural Terminology (CPT®) codes, inpatient admission, and 
LOCM or iso-osmolar CM agent. Renal failure during the visit was determined by 
ICD-9 diagnosis codes. Two different statistical approaches were employed to assess 
the relationship between renal failure and CM use – Ordinary Least Squares (OLS) 
cross-sectional and hospital fixed-effects model specification. Results: A total of 
385,290 interventional procedure visits met the inclusion criteria. The unadjusted 
univariate analysis showed 1.7% (p< 0.01) more renal events in the iso-osmolar 
CM cohort compared to LOCM. The most saturated (OLS) cross-sectional analysis 
showed 1.4% (p< 0.01) fewer renal events in the iso-osmolar CM cohort compared 
to patients who received LOCM. Controlling for unobserved heterogeneity across 
hospitals using the most saturated hospital fixed-effect specification, we found 
2.3% (p < 0.01) fewer renal failure events with iso-osmolar CM. ConClusions: This 
study illustrated the importance of controlling for observable and for unobserv-
able, within-hospital time invariant characteristics through a hospital fixed-effects 
specification when the decision-making factors for selection of CM may vary from 
hospital to hospital.
PRM4
A STUDy ON CyTOgENETIC AND MOlECUlAR ANAlySIS Of PRESENIlIN 1 (PS1) 
gENE IN AlzHEIMER’S DISEASE
Mohana Devi S1, Sasikala K2, Balachandar V2
1Dankook University, Chungnam, South Korea, 2Bharathiar University, Coimbatore, India
objeCtives: Alzheimer’s disease (AD), the most common form of dementia, is a 
degenerative disorder of the brain that leads to memory loss. Oxidative stress is a 
hallmark of AD. This study aims to identify the genetic alterations of AD by using the 
conventional cytogenetic technique by Trypsin G- banding and molecular analysis 
of presenilin 1 (PS1) genotype by PCR. The role of selected ions related to energy 
metabolism as a consequence of oxidative stress in the deterioration accompa-
nied in AD patients were also analyzed. Methods: The present study includes 
49 AD patients and the subjects were categorized in two groups (14 Early-Onset 
AD) patients and (31 Late- Onset AD) patients, in order to investigate the possible 
cytogenetic and molecular damage. The gels were developed by staining with silver 
nitrate. Results: The Late- Onset AD patient shows higher total CA level when 
compared to Early-Onset AD patient. A comparison of the frequencies for PS1 geno-
types among the Early-Onset AD and Late- Onset AD subjects demonstrated a sig-
nificant difference between the two groups. ConClusions: The strong association 
of PS1 with Late- Onset AD patients called attention to the importance of genetic 
studies in AD and the possible roles of PS1 in the progression of this disease. Based 
on the contributing effects of PS1 in AD pathogenesis, targeting PS1 may provide new 
opportunities for AD therapeutic strategies. Key Words: Early-Onset Alzheimer’s 
disease patient, Late- Onset Alzheimer’s disease patients, PS1, PCR – RFLP
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HOw gOOD ARE PHySICIANS AND CHART REVIEwS AT CAPTURINg HEAlTH 
RESOURCES AND DRUg UTIlISATION by PATIENTS? RESUlTS Of THE PgRx-3 
PROSPECTIVE REAl wORlD DATASET VAlIDATION STUDy
Grimaldi-Bensouda L1, Rossignol M2, Worsfold A3, Nordon C1, Abenhaim L3
1LASER Research, Paris, France, 2McGill University, Montreal, QC, Canada, 3LASER Analytica, 
London, UK
objeCtives: To compare physicians and patient’s reports of health resource uti-
lisation using the PGRx-3 datasets. Methods: PGRx (Pharmacoepidemiologic 
General Research eXtension) is a multiusers, multi-countries, prospective Real 
World Datasets originally assembled for effectiveness and relative risk of medicines 
research. In 2015, PGRx was extended to HEOR research in six countries (France, 
UK, Italy, Germany, Spain and in the US). Diseases studied with the PGRx meth-
odology are: acute coronary syndrome, arrhythmias, stroke, lupus, rheumatoid 
arthritis, multiple sclerosis, Guillain Barré Syndrome, type I diabetes, autoimmune 
thyroiditis, depression and suicide attempts, paediatric autoimmune disorders, 
breast cancer, prostate cancer (on-going) and others. Patients are recruited by board-
certified specialists or general practitioners and they can fill self-questionnaires. 
More than 65% consenting patients also undergo a telephone interview. All PGRx 
datasets are submitted for ethics and privacy protection committees’ approval in 
the contemplated countries. Medical records of more than 5,000 patients have been 
obtained in a series of validation studies including several of the PGRx disorders and 
results compared to interviews of the same patients on health resources and drug 
utilisation. Results: An agreement superior to 95% between patients and their 
physician’s medical records was observed for report of chronic drug use and vac-
cines, but the agreement was low (< 30%) for drugs available OTC or in the patients’ 
pharmacy (eg: NSAIDs) and for patients’ health resources utilisation (eg: physician 
visits) (agreement less than 25%). ConClusions: Physicians have poor knowledge 
of acute drug use and of health resource utilisation by patients. Patient interviews 
are more valid sources of information for health economics and outcomes research 
than chart reviews
